TRCT
CTKB icon

Tower Research Capital (TRC)’s Cytek Biosciences CTKB Stock Holding History

Tower Research Capital (TRC)’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.7K Buy
10,240
+7,002
+216% +$33.1K ﹤0.01% 2837
2025
Q4 		$16.4K Sell
3,238
-4,637
-59% -$21.5K ﹤0.01% 3256
2025
Q3 		$27.3K Sell
7,875
-11,885
-60% -$44.6K ﹤0.01% 3030
2025
Q2 		$67.2K Buy
19,760
+15,250
+338% +$50.8K ﹤0.01% 2719
2025
Q1 		$18.1K Buy
4,510
+1,421
+46% +$7.37K ﹤0.01% 3064
2024
Q4 		$20K Buy
3,089
+687
+29% +$4.09K ﹤0.01% 3180
2024
Q3 		$13.3K Sell
2,402
-14,652
-86% -$83.1K ﹤0.01% 3526
2024
Q2 		$95.2K Buy
17,054
+15,658
+1,122% +$94K ﹤0.01% 2621
2024
Q1 		$9.37K Sell
1,396
-34,890
-96% -$276K ﹤0.01% 3856
2023
Q4 		$331K Buy
36,286
+30,475
+524% +$192K ﹤0.01% 1701
2023
Q3 		$32.1K Buy
5,811
+2,362
+68% +$18.9K ﹤0.01% 2967
2023
Q2 		$29.5K Sell
3,449
-8,373
-71% -$75.1K ﹤0.01% 3034
2023
Q1 		$109K Sell
11,822
-504
-4% -$5.42K ﹤0.01% 1789
2022
Q4 		$125K Buy
12,326
+4,082
+50% +$54.9K 0.01% 1650
2022
Q3 		$121K Buy
8,244
+4,393
+114% +$57.1K ﹤0.01% 2401
2022
Q2 		$41K Buy
3,851
+1,966
+104% +$19.6K ﹤0.01% 3077
2022
Q1 		$20K Buy
1,885
+436
+30% +$5.89K ﹤0.01% 3524
2021
Q4 		$23K Buy
1,449
+940
+185% +$19.7K ﹤0.01% 3501
2021
Q3 		$11K Buy
+509
New +$12K ﹤0.01% 4213

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tower Research Capital (TRC)'s CTKB Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Cytek Biosciences (CTKB) stake by 216% in Q1 2026, buying an estimated $33.1K and bringing the position to 10,240 shares worth $44.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2837.

Tower Research Capital (TRC) first reported a position in CTKB in Q3 2021 and has held it in 19 quarters since. The position peaked at $331K in Q4 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Tower Research Capital (TRC) held 10,240 shares of Cytek Biosciences worth $44.7K as of Q1 2026.
  • Tower Research Capital (TRC) bought 7,002 Cytek Biosciences shares in Q1 2026, an estimated $33.1K.
  • Cytek Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2837 holding.
  • Tower Research Capital (TRC) first reported a position in Cytek Biosciences in Q3 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Cytek Biosciences position peaked at $331K in Q4 2023.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.